BI 51013

Drug Profile

BI 51013

Alternative Names: Anti-alpha-beta-TCR monoclonal antibody BMA-031; Anti-T cell receptor alphabeta monoclonal antibody BMA031; Anti-TCR-alphabeta monoclonal antibody BMA031; Behring Monoclonal Antibody; BMA 031; Monoclonal antibody BMA031

Latest Information Update: 26 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aventis Behring LLC
  • Developer Aventis Behring
  • Class Monoclonal antibodies
  • Mechanism of Action T-cell receptor antigen alpha-beta antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Graft-versus-host disease; Renal transplant rejection; Transplant rejection

Most Recent Events

  • 25 Jan 2017 Discontinued - Phase-II for Graft-versus-host disease in Germany, USA (unspecified route)
  • 25 Jan 2017 Discontinued - Phase-III for Renal transplant rejection in USA, Germany (IV)
  • 25 Jan 2017 Discontinued - Preclinical for Transplant rejection in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top